Literature DB >> 22325171

A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease.

J S Halliday1, J Djordjevic, M Lust, E L Culver, B Braden, S P L Travis, R W G Chapman.   

Abstract

BACKGROUND AND AIMS: A distinct clinical phenotype has been demonstrated for ulcerative colitis with concomitant primary sclerosing cholangitis (PSC). The course and behaviour of Crohn's disease (CD) with PSC has, in contrast, never been defined. We aimed to define the characteristics of patients with concomitant PSC and CD.
METHODS: The Oxford PSC and IBD databases were abstracted for: PSC subtype, date of diagnosis, symptom onset, smoking history, Mayo Clinic PSC score and outcomes (hepatic failure, liver transplantation, Montréal CD classification, treatment, cancer and death). Patients with PSC/CD were matched 1:2 to two control groups: one with PSC/UC and one with isolated CD.
RESULTS: 240 patients with PSC were identified; 32 (13%) with CD, 129 (54%) with co-existing UC, and 79 had PSC without IBD. For PSC/CD vs. CD controls, isolated ileal CD was less common (6% vs. 31%, p=0.03). Smoking was less common in PSC/CD (13% vs. 34%, p=0.045). No difference in the distribution of CD, or treatment required was observed. For PSC/CD vs. PSC/UC controls, more patients with PSC/CD were female (50% vs. 28%, p=0.021). 22% of PSC/CD patients had small duct PSC compared with 6% with PSC/UC, (p=0.038). Major event-free survival was prolonged in the PSC/CD group compared with PSC/UC, (Cox regression p=0.04).
CONCLUSION: Unlike PSC/UC, patients with PSC/CD were as likely to be female as male, more commonly had small duct PSC and less commonly progressed to cancer, liver transplantation, or death. Compared to patients with isolated CD, patients with PSC/CD were less likely to smoke or have ileal disease.
Copyright © 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22325171     DOI: 10.1016/j.crohns.2011.07.015

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  20 in total

Review 1.  Hepatic Manifestations of Inflammatory Bowel Disease.

Authors:  Parita Patel; Sushila Dalal
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-05-01

2.  Impact of Crohn's Disease Duration on the Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis.

Authors:  De-Jun Cui; Xun Zhao; Mei Hu
Journal:  Am J Gastroenterol       Date:  2017-01       Impact factor: 10.864

Review 3.  Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.

Authors:  A Boudewijn de Vries; Marcel Janse; Hans Blokzijl; Rinse K Weersma
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

4.  Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.

Authors:  Tobias J Weismüller; Palak J Trivedi; Annika Bergquist; Mohamad Imam; Henrike Lenzen; Cyriel Y Ponsioen; Kristian Holm; Daniel Gotthardt; Martti A Färkkilä; Hanns-Ulrich Marschall; Douglas Thorburn; Rinse K Weersma; Johan Fevery; Tobias Mueller; Olivier Chazouillères; Kornelius Schulze; Konstantinos N Lazaridis; Sven Almer; Stephen P Pereira; Cynthia Levy; Andrew Mason; Sigrid Naess; Christopher L Bowlus; Annarosa Floreani; Emina Halilbasic; Kidist K Yimam; Piotr Milkiewicz; Ulrich Beuers; Dep K Huynh; Albert Pares; Christine N Manser; George N Dalekos; Bertus Eksteen; Pietro Invernizzi; Christoph P Berg; Gabi I Kirchner; Christoph Sarrazin; Vincent Zimmer; Luca Fabris; Felix Braun; Marco Marzioni; Brian D Juran; Karouk Said; Christian Rupp; Kalle Jokelainen; Maria Benito de Valle; Francesca Saffioti; Angela Cheung; Michael Trauner; Christoph Schramm; Roger W Chapman; Tom H Karlsen; Erik Schrumpf; Christian P Strassburg; Michael P Manns; Keith D Lindor; Gideon M Hirschfield; Bettina E Hansen; Kirsten M Boberg
Journal:  Gastroenterology       Date:  2017-03-06       Impact factor: 22.682

Review 5.  The IBD and PSC Phenotypes of PSC-IBD.

Authors:  Amanda Ricciuto; Binita M Kamath; Anne M Griffiths
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

6.  ACG Clinical Guideline: Primary Sclerosing Cholangitis.

Authors:  Keith D Lindor; Kris V Kowdley; M Edwyn Harrison
Journal:  Am J Gastroenterol       Date:  2015-04-14       Impact factor: 10.864

Review 7.  Primary sclerosing cholangitis: diagnosis, prognosis, and management.

Authors:  Siddharth Singh; Jayant A Talwalkar
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-27       Impact factor: 11.382

8.  Comparison of outcomes for patients with primary sclerosing cholangitis associated with ulcerative colitis and Crohn's disease.

Authors:  Udayakumar Navaneethan; Preethi Gk Venkatesh; Ramprasad Jegadeesan; Vennisvasanth Lourdusamy; Jeffrey P Hammel; Ravi P Kiran; Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-10-29

Review 9.  Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.

Authors:  Palak J Trivedi; Christophe Corpechot; Albert Pares; Gideon M Hirschfield
Journal:  Hepatology       Date:  2015-11-26       Impact factor: 17.425

10.  Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohn's disease.

Authors:  Mohamed Attauabi; Mirabella Zhao; Flemming Bendtsen; Johan Burisch
Journal:  Therap Adv Gastroenterol       Date:  2021-06-22       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.